New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone triggers payments to it totalling USD29 million under agreements with Royalty Pharma and Karuna Therapeutics,
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental illness in more than 30 years.
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to target cholinergic receptors rather than dopamine receptors,
First New Schizophrenia Treatment Approach In Decades Gets FDA Approval
The US Food and Drug Administration (FDA) has just approved a new drug for the treatment of schizophrenia. Marketed under the name Cobenfy, the medication combines two different drugs that together target a totally different mechanism in the brain than conventional antipsychotics,
Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment
Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company's new schizophrenia treatment,
bovnews3d
Royalty Pharma plc (RPRX) Posted 30.07% Profit Margin Last Year—Can It Hold Up?
UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...
news.stocktradersdaily9d
Long Term Trading Analysis for (RPRX)
Check the time stamp on this data. Updated AI-Generated Signals for Royalty Pharma Plc (RPRX) available here: RPRX.
Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over ...
bovnews5d
UBS Issues Neutral Rating for Royalty Pharma plc (RPRX) Stock
On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...
10 Best Affordable Stocks To Buy Right Now
The stock market appears to be at a turning point. While major indexes are still hovering near record levels, there ...
MarketWatch12d
S&P 500 Futures Up in Premarket Trading; Manhattan Associates, Casella Waste Sys Lag
With U.S. stock markets set to open in two hours, United States Steel Corp. (X) was up 3.5% in pre-market trading, and Royalty Pharma PLC (RPRX) was up 2.9%.
Hosted on MSN3d
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...
EARNINGS: Alliance Pharma swings to profit; DG Innovate loss widens
The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of ...
Aviation Week11d
Royalty, Government Attend Airbus Helicopters UK Headquarters Opening
Royalty, Government Attend Airbus Helicopters UK Headquarters Opening is published in Aerospace Daily & Defense Report, an ...